{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:46:11Z","timestamp":1785577571012,"version":"3.56.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["R01 CA231239"],"award-info":[{"award-number":["R01 CA231239"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011331","name":"Monique Weill-Caulier Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014276","name":"Pershing Square Sohn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014276","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Irving Institute Pilot"},{"DOI":"10.13039\/100031313","name":"Herbert Irving Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["P30CA013696"],"award-info":[{"award-number":["P30CA013696"]}],"id":[{"id":"10.13039\/100031313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031313","name":"Herbert Irving Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["P30CA013696"],"award-info":[{"award-number":["P30CA013696"]}],"id":[{"id":"10.13039\/100031313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cachexia is characterized by weight loss and decline in muscle mass and function and is a poor prognostic factor among patients with cancer. Patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC) derive remarkable survival benefits with osimertinib, a third-generation EGFR tyrosine kinase inhibitor. It is not known whether patients treated with osimertinib experience any weight loss or whether weight loss impacts patient outcomes. Therefore, we sought to describe the frequency and consequences of weight loss in this patient population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and methods<\/jats:title>\n                  <jats:p>We conducted a single-center retrospective pilot study of 56 patients treated with first-line osimertinib for metastatic EGFR-mutant NSCLC. We defined on-treatment weight loss as a loss of \u22655% body weight at 6 or 12 months of treatment. We described the characteristics of patients with and without on-treatment weight loss and differences in progression-free survival (PFS), time on treatment with osimertinib, and overall survival (OS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty-six percent (n\u2005=\u200526) of patients met the criteria for on-treatment weight loss. There were no significant differences in patient or disease characteristics between patients with and without weight loss. Compared to patients without weight loss, patients with weight loss had similar PFS and time on treatment with osimertinib. Yet, patients with weight loss had significantly worse overall survival (HR 4.91, 95% CI, 1.56-15.5, P\u2005=\u2005.007).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Weight loss was observed in nearly half of patients with metastatic EGFR-mutant NSCLC treated with osimertinib, and patients with weight loss had significantly worse overall survival.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae315","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T03:37:52Z","timestamp":1734665872000},"source":"Crossref","is-referenced-by-count":4,"title":["Weight loss in patients on osimertinib for metastatic <i>EGFR<\/i>-mutant non-small cell lung cancer"],"prefix":"10.1093","volume":"30","author":[{"given":"Lanyi Nora","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center , New York, NY 10032 ,","place":["United States"]},{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center New York, NY 10032 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ma","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center New York, NY 10032 ,","place":["United States"]},{"name":"Department of Statistics, Columbia University Irving Medical Center , New York, NY 10032 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3253-3106","authenticated-orcid":false,"given":"Benjamin","family":"Herzberg","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center , New York, NY 10032 ,","place":["United States"]},{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center New York, NY 10032 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S","family":"Henick","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center , New York, NY 10032 ,","place":["United States"]},{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center New York, NY 10032 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-7226","authenticated-orcid":false,"given":"Anup K","family":"Biswas","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center New York, NY 10032 ,","place":["United States"]},{"name":"Institute for Cancer Genetics and Department of Pathology and Cell Biology, Columbia University Irving Medical Center , New York, NY 10032 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-6881","authenticated-orcid":false,"given":"Swarnali","family":"Acharyya","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center New York, NY 10032 ,","place":["United States"]},{"name":"Institute for Cancer Genetics and Department of Pathology and Cell Biology, Columbia University Irving Medical Center , New York, NY 10032 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A","family":"Shu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center , New York, NY 10032 ,","place":["United States"]},{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center New York, NY 10032 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"2025082905271568700_CIT0001","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41568-020-0251-4","article-title":"Understanding cachexia in the context of metastatic progression","volume":"20","author":"Biswas","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"2025082905271568700_CIT0002","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/jcsm.12402","article-title":"Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review","volume":"10","author":"Anker","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2025082905271568700_CIT0003","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"2025082905271568700_CIT0004","doi-asserted-by":"publisher","first-page":"e165419","DOI":"10.1172\/jci.insight.165419","article-title":"Tumor loss-of-function mutations in STK11\/LKB1 induce cachexia","volume":"8","author":"Iyengar","year":"2023","journal-title":"JCI Insight"},{"key":"2025082905271568700_CIT0005","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1200\/OP.22.00674","article-title":"Race, ethnicity, and socioeconomic factors as determinants of cachexia incidence and outcomes in a retrospective cohort of patients with gastrointestinal tract cancer","volume":"19","author":"Olaechea","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"2025082905271568700_CIT0006","doi-asserted-by":"publisher","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat Rev Dis Prim."},{"key":"2025082905271568700_CIT0007","doi-asserted-by":"publisher","first-page":"43442","DOI":"10.18632\/oncotarget.9779","article-title":"Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1\/2 and p38 MAPKs","volume":"7","author":"Barreto","year":"2016","journal-title":"Oncotarget"},{"key":"2025082905271568700_CIT0008","doi-asserted-by":"publisher","first-page":"7590","DOI":"10.4081\/ejtm.2018.7590","article-title":"Chemotherapy-induced muscle wasting: association with NF-\u03baB and cancer cachexia","volume":"28","author":"Damrauer","year":"2018","journal-title":"Eur J Transl Myol"},{"key":"2025082905271568700_CIT0009","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/MCO.0000000000000922","article-title":"Adverse effects of systemic cancer therapy on skeletal muscle: myotoxicity comes out of the closet","volume":"26","author":"Klassen","year":"2023","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"2025082905271568700_CIT0010","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3390\/ijms21041242","article-title":"Cisplatin-induced skeletal muscle dysfunction: mechanisms and counteracting therapeutic strategies","volume":"21","author":"Conte","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025082905271568700_CIT0011","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","article-title":"Understanding the mechanisms and treatment options in cancer cachexia","volume":"10","author":"Fearon","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"2025082905271568700_CIT0012","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"2025082905271568700_CIT0013","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/1759-7714.12910","article-title":"Updates on the pathogenesis of advanced lung cancer-induced cachexia","volume":"10","author":"Zhu","year":"2019","journal-title":"Thorac Cancer"},{"key":"2025082905271568700_CIT0014","doi-asserted-by":"publisher","first-page":"e389942","DOI":"10.1200\/EDBK_389942","article-title":"Current therapeutic targets in cancer cachexia: a pathophysiologic approach","volume":"43","author":"Kadakia","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"2025082905271568700_CIT0015","doi-asserted-by":"publisher","first-page":"e0285850","DOI":"10.1371\/journal.pone.0285850","article-title":"Phase II, double blind, placebo controlled, multi-site study to evaluate the safety, feasibility and desirability of conducting a phase III study of anamorelin for anorexia in people with small cell lung cancer: A study protocol (LUANA trial)","volume":"18","author":"Sousa","year":"2023","journal-title":"PLoS One"},{"key":"2025082905271568700_CIT0016","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2409515","article-title":"Ponsegromab for the Treatment of Cancer Cachexia [published online ahead of print September 14, 2024]","author":"Groarke","journal-title":"N\u00a0Engl J Med"},{"key":"2025082905271568700_CIT0017","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/MCO.0000000000000272","article-title":"Diagnostic criteria for cancer cachexia: data versus dogma","volume":"19","author":"Martin","year":"2016","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"2025082905271568700_CIT0018","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/s1470-2045(00)00033-4","article-title":"Cachexia and asthenia in cancer patients","volume":"1","author":"Bruera","year":"2000","journal-title":"Lancet Oncol"},{"key":"2025082905271568700_CIT0019","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab"},{"key":"2025082905271568700_CIT0020","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.nut.2019.03.012","article-title":"Mediators of cachexia in cancer patients","volume":"66","author":"Argil\u00e9s","year":"2019","journal-title":"Nutrition"},{"key":"2025082905271568700_CIT0021","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2017","journal-title":"N Engl J Med"},{"key":"2025082905271568700_CIT0022","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/sj.bjc.6601781","article-title":"Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers","volume":"90","author":"Ross","year":"2004","journal-title":"Br J Cancer"},{"key":"2025082905271568700_CIT0023","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1200\/JCO.20.00611","article-title":"Management of cancer cachexia: ASCO guideline","volume":"38","author":"Roeland","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025082905271568700_CIT0024","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"2025082905271568700_CIT0025","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"2025082905271568700_CIT0026","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"2025082905271568700_CIT0027","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in Untreated ALK-positive non\u2013small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"2025082905271568700_CIT0028","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"2025082905271568700_CIT0029","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0149-2918(05)80001-3","article-title":"Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group","volume":"69","author":"Dewys","year":"1980","journal-title":"Am J Med"},{"key":"2025082905271568700_CIT0030","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.semcdb.2015.09.001","article-title":"Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes","volume":"54","author":"Kazemi-Bajestani","year":"2016","journal-title":"Semin Cell Dev Biol"},{"key":"2025082905271568700_CIT0031","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12904-019-0429-2","article-title":"A prospective study examining cachexia predictors in patients with incurable cancer","volume":"18","author":"Vagnildhaug","year":"2019","journal-title":"BMC Palliat Care"},{"key":"2025082905271568700_CIT0032","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/B978-0-323-83404-9.00009-8","volume-title":"Chapter 5 - Lung Cancer in the Palliative Care Setting: Successes, Challenges, and Opportunities for Collaboration","author":"Medina","year":"2023"},{"key":"2025082905271568700_CIT0033","doi-asserted-by":"publisher","first-page":"6127","DOI":"10.3390\/cancers14246127","article-title":"TP53 co-mutation status association with clinical outcomes in patients with EGFR-mutant non-small cell lung cancer","volume":"14","author":"Le","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025082905271568700_CIT0034","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/SPC.0b013e328331124a","article-title":"The emerging role of computerized tomography in assessing cancer cachexia","volume":"3","author":"Prado","year":"2009","journal-title":"Curr Opin Support Palliat Care"},{"key":"2025082905271568700_CIT0035","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1172\/JCI138392","article-title":"Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease-associated cachexia","volume":"130","author":"Zhu","year":"2020","journal-title":"J Clin Invest"},{"key":"2025082905271568700_CIT0036","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41591-018-0054-2","article-title":"Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle","volume":"24","author":"Wang","year":"2018","journal-title":"Nat Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyae315\/61242995\/oyae315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/8\/oyae315\/61242995\/oyae315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:27:25Z","timestamp":1756459645000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae315\/7929273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae315","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2024,12,19]]},"article-number":"oyae315"}}